HSBC Holdings’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

HSBC Holdings’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-529,071	Closed	-$21.7M	–	3219
2024 Q2	$21.7M	Buy	529,071 +121,261	+30%	+$5.05M	0.01%	662
2024 Q1	$17.2M	Sell	407,810 -222	-0.1%	-$9.32K	0.01%	731
2023 Q4	$17.3M	Buy	+408,032	New	+$11.7M	0.02%	718
2021 Q2	–	Sell	-10,518	Closed	-$140K	–	3120
2021 Q1	$140K	Sell	10,518 -10,485	-50%	-$153K	﹤0.01%	2598
2020 Q4	$357K	Buy	+21,003	New	+$273K	﹤0.01%	2451

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HSBC Holdings's CERE Position: Q3 2024 in Review

HSBC Holdings sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 529,071 shares — an estimated $21.7M sold.

HSBC Holdings first reported a position in CERE in Q4 2020 and held it in 5 quarters. The position peaked at $21.7M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

HSBC Holdings reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
HSBC Holdings sold 529,071 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $21.7M.
HSBC Holdings first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
HSBC Holdings's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $21.7M in Q2 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on HSBC Holdings's 13F filing for Q3 2024, filed 14 Nov 2024.